Inhibitor Therapeutics, Inc.
OTC: INTI0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Francis E. O'Donnell Jr.
- Employees
- 3
- Headquarters
- Tampa, United States
- IPO year
- 2013
- Market cap
- $13.3M
- Website
- https://www.inhibitortx.com
Loading INTI…
Loading profile data…Frequently asked questions about INTI
What does Inhibitor Therapeutics, Inc. (INTI) do?
Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida, is a pharmaceutical development enterprise. The company is dedicated to inventing and commercializing medical treatments for patients in the United States who suffer from various cancerous and non-cancerous cell proliferation conditions. A primary focus of their work...
Where does INTI trade?
Inhibitor Therapeutics, Inc. (INTI) trades on the Other OTC.
What sector is INTI in?
Inhibitor Therapeutics, Inc. (INTI) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Inhibitor Therapeutics, Inc.?
Francis E. O'Donnell Jr. is the chief executive officer of Inhibitor Therapeutics, Inc. (INTI).
Where is Inhibitor Therapeutics, Inc. headquartered?
Inhibitor Therapeutics, Inc. is headquartered in United States.
Does INTI pay a dividend?
Inhibitor Therapeutics, Inc. (INTI) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did INTI go public?
Inhibitor Therapeutics, Inc. (INTI) completed its initial public offering in 2013.